BACKGROUND: Topical @entity2176 may be an effective intervention to decrease the risk of postoperative surgical site infections (SSIs). The primary objective of this study was to evaluate the impact of topical @entity2176 with intravenous (IV) @entity7048 compared with IV @entity7048 alone on the incidence of SSI in instrumented multilevel spinal fusion (MLSF) surgery. METHODS: This was a retrospective cohort study of @entity1 18  years and older who underwent instrumented MLSF surgery between January 1, 2010, and July 31, 2014. @entity1 who underwent anterior cervical diskectomy and fusion, had spine surgery within 3  months prior to index case, received antibiotics other than IV @entity7048 prior to surgery, or had preoperative length of stay longer than 5  days were excluded. SSIs were identified using Centers for Disease Control and Prevention National Healthcare Safety Network definitions. Summary statistics were computed. Variables found to be associated with increased risk of SSI through univariate analysis were included in a multivariate analysis. RESULTS: Among 326 @entity1 , 29 (8.9%) developed an SSI. Univariate analysis showed a trend toward decreased SSI incidence in the cohort receiving topical @entity2176 with IV @entity7048 compared with IV @entity7048 alone, although this was not statistically significant ([6/116] 5.2% vs [23/210] 11.0%, p  =  0.08). Topical @entity2176 was associated with a protective effect against SSI in the multivariate analysis (odds ratio [OR] 0.26, p  =  0.02). Significant risk factors for the development of SSI included female sex ( @entity40489 , p  =  0.01), increasing invasiveness score (p  <  0.01), and @entity6 (OR 5.1, p  <  0.01). CONCLUSION: Topical @entity2176 administered in addition to IV @entity7048 was associated with a decreased risk of SSI in high-risk MLSF @entity1 . Female @entity1 and those with @entity6 were at higher risk of developing @entity281 . Further prospective studies are needed to confirm these results and to define the most clinically effective dose of topical @entity2176 in this @entity1 population.

A Retrospective Study on the Protective Effects of Topical XXXX in @entity1 Undergoing Multilevel Spinal Fusion.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity40489 :: ('79297', 'Gene') :: ['OR 3.3'] @entity2176 :: ('MESH:D014640', 'Chemical') :: ['vancomycin'] @entity7048 :: ('MESH:D002437', 'Chemical') :: ['cefazolin'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity281 :: ('MESH:D007239', 'Disease') :: ['postsurgical infection']
@entity2176 :: (MESH:D014640,Chemical) :: ['Vancomycin']
